Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT04120298

Effects of Exercise in Patients With Metastatic Breast Cancer

Currently, the effect of exercise on metastatic breast cancer has not been extensively studied, even though the benefits are evident in the curative setting. The investigators designed the EFFECT study to assess the effects of a 9-month structured and individualised exercise intervention in 350 patients with metastatic breast cancer (stage IV) on cancer-related physical fatigue, Health-Related Quality of Life (HRQoL), and other disease and treatment-related side effects at six months (primary endpoint).

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University Medical Center Utrecht

Utrecht, Netherlands

About this study

The EFFECT study is a multicentre, randomised controlled trial. The intervention group will participate in a 9-month exercise intervention. The exercise program will start with a 6-month period, where patients participate in a supervised multimodal exercise program twice a week supplemented with unsupervised exercises. The multimodal exercise program comprises aerobic-, resistance- and balance components. After completing the initial six-month period, one supervised session will be replaced by one unsupervised session until month nine.

Unsupervised exercises will be supported by an activity tracker (FitBit) and an exercise App specifically designed for the EFFECT trial. Patients randomized to the control group will also receive an activity tracker (like the intervention group). The investigators will advice control patients to avoid inactivity and be as physically active as current abilities and conditions allow, with the aim to progress towards being physically active for 150min/week in line with the current exercise guidelines.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of breast cancer stage IV
  • ECOG (Eastern Cooperative Oncology Group scale) performance status ≤ 2
  • Able and willing to perform the exercise program and wear the activity tracker

Exclusion criteria

  • A potential subject who meets any of the following criteria is not eligible for enrolment into this study:
  • Unstable bone metastases inducing skeletal fragility as determined by the treating clinician
  • Untreated symptomatic known brain metastasis
  • Estimated life expectancy < 6 months as determined by the treating clinician
  • Serious active infection
  • Too physically active (i.e. >210 minutes/week of moderate-to-vigorous intentional exercise
  • Severe neurologic or cardiac impairment according ACSM criteria
  • Uncontrolled severe respiratory insufficiency as determined by the treating clinician or if the patient is dependent on oxygen suppletion in rest or during exercise
  • Uncontrolled severe pain
  • Any other contraindications for exercise as determined by the treating physician
  • Any circumstances that would impede adherence to study requirements or ability to give informed consent, as determined by the treating clinician
  • Pregnancy

Treatment and study plan

Supervised exercise

Behavioral

An individualised exercise programme supervised by a trained instructor

Primary outcomes

  1. Cancer-related physical fatigue

    Time frame: 0- 6 months (measured at baseline, 3 and 6 months)

    Physical fatigue measured with the EORTC QLQ-FA12

  2. Health-related Quality of Life

    Time frame: 0- 6 months (measured at baseline, 3 and 6 months)

    Disease specific HRQoL measured with the EORTC QLQ-C30 Summary Score

Secondary outcomes

  1. Separate HRQoL domains and Summary Score

    Time frame: 0-9 months

    EORTC QLQ-C30 function and symptom scores scores

  2. Cancer-related fatigue

    Time frame: 0-9 months

    EORTC QLQ-FA12 scores

  3. Breast cancer specific symptoms

    Time frame: 0-9 months

    EORTC QLQ-BR45

  4. Anxiety, depression

    Time frame: 0-9 months

    PHQ-4

  5. Sleep

    Time frame: 0-9 months

    PSQI

  6. Pain: severity and its impact on functioning.

    Time frame: 0-9 months

    BPI

  7. Neuropathic pain

    Time frame: 0-9 months

    painDETECT

  8. Pain Catastrophizing

    Time frame: 0-9 months

    PCS

  9. Treatment-related toxicities grade≥3

    Time frame: 0-9 months

    Common Toxicity Criteria for adverse events (CTCAE)

  10. Weight

    Time frame: 0-6 months

    weight measured in KG

  11. Height

    Time frame: 0-6 months

    Height measured in meters

  12. Waist circumference

    Time frame: 0-6 months

    waist circumference measured in cm

  13. Body composition (fat free mass and fat mass)

    Time frame: 0-6 months

    Bioelectrical impedance analysis (BIA), add-on in some centers (not obligatory): DEXA

  14. Physical activity (subjective)

    Time frame: 0-6-9 months

    Questionnaire

  15. Physical activity (objective)

    Time frame: 0-6-9 months

    activity tracker

  16. Resting heart rate

    Time frame: 0-6 months

    Resting heart rate

  17. Blood pressure

    Time frame: 0-6 months

    Blood pressure (diastolic and systolic) measured at rest

  18. Physical performance

    Time frame: 0-6 months

    Short Physical Performance Battery, handgrip- and leg strength test

  19. Physical fitness

    Time frame: 0-6 months

    Steep ramp test and endurance cycle test, add-on (not obligatory): CPET

  20. Work status/ healthcare resources consumption

    Time frame: 0-9 months

    iPCQ/iMCQ

  21. Intervention costs

    Time frame: 0-9 months

    Cost analyses

  22. Health status

    Time frame: 0-9 months

    EQ-5D-5L

  23. Satisfaction with exercise intervention

    Time frame: 0-9 months

    Self-developed questionnaire

  24. Biomarkers (systemic inflammation, growth factors, blood/brain barrier modulators)

    Time frame: 0-6 months

    Blood samples (plasma, serum, buffy coat and peripheral blood mononuclear cells (PBMC) )

  25. Disease control

    Time frame: 0-9 months

    Progress or disease control of the breast cancer will be derived from medical records and/or the cancer registry

  26. Cancer treatment

    Time frame: 0-9 months

    The type and duration of cancer treatment during the study will be derived from medical records and/or the cancer registry

  27. Quality of working life

    Time frame: 0-9 months

    QWLQ-CS (add-on in several centers)

Other outcomes

  1. Overall and breast-cancer specific survival

    Time frame: 0-60 months

    Exploratory outcome

  2. Progression-free survival

    Time frame: 0-60 months

    Exploratory outcome

  3. Safety of exercise intervention

    Time frame: 0-9 months

    (Serious) Adverse events potentially related to the exercise intervention

  4. Urinary incontinence

    Time frame: 0-9 months

    Exploratory outcome (add on in some centers) - measured with ICIQ-UI

  5. Maximal isokinetic and isometric leg strength, muscle thickness of m. rectus femoris (RF) and m. vastus lateralis (VL)

    Time frame: 0-9 months

    Exploratory outcome (add on in one center) - Isokinetic and isometric legstrength measured with peak torque / Muscle thickness with ultrasound protocol

Sponsors and collaborators

Lead sponsor

UMC Utrecht

Other

Collaborators

  • Australian Catholic University
  • Europa Donna
  • Fundación Onkologikoa Fundazioa
  • German Cancer Research Center
  • German Sport University, Cologne
  • Karolinska Institutet
  • Medical University of Gdansk
  • Nurogames GmbH, Cologne
  • The Netherlands Cancer Institute
  • University Hospital Heidelberg

Registry information

Official study title

Effects of Structured and Individualized Exercise in Patients With Metastatic Breast Cancer on Fatigue and Quality of Life

Acronym: EFFECT

Important dates

Study start
2020
Primary completion
2023
Study completion
2027
First posted
Oct 9, 2019
Registry last updated
May 11, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.